摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N'-{(E)-[2-hydroxy-3-(prop-2-en-1-yl)phenyl]methylidene}-2-[4-(4-methylbenzyl)piperazin-1-yl]acetohydrazide

中文名称
——
中文别名
——
英文名称
N'-{(E)-[2-hydroxy-3-(prop-2-en-1-yl)phenyl]methylidene}-2-[4-(4-methylbenzyl)piperazin-1-yl]acetohydrazide
英文别名
N-[(E)-(2-hydroxy-3-prop-2-enylphenyl)methylideneamino]-2-[4-[(4-methylphenyl)methyl]piperazin-1-yl]acetamide
N'-{(E)-[2-hydroxy-3-(prop-2-en-1-yl)phenyl]methylidene}-2-[4-(4-methylbenzyl)piperazin-1-yl]acetohydrazide化学式
CAS
——
化学式
C24H30N4O2
mdl
——
分子量
406.5
InChiKey
LJVVVFLTXKEVCD-PCLIKHOPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    30
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    72.2
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS
    申请人:Hergenrother Paul J.
    公开号:US20120040995A1
    公开(公告)日:2012-02-16
    Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    本实施例揭示了与诱导细胞死亡有关的组合物和方法,例如在癌细胞中。揭示了合成和使用相关化合物的方法,包括在治疗癌症和选择性诱导细胞凋亡方面使用化合物的方法。揭示了具有比其他化合物更低神经毒性影响的化合物。
  • PROCASPASE ACTIVATING COMPOUNDS
    申请人:The Board of Trustees of the University of Illinois
    公开号:US20150344452A1
    公开(公告)日:2015-12-03
    Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    本实施例揭示了与细胞死亡诱导有关的组合物和方法,例如在癌细胞中。揭示了合成和使用相关化合物的方法,包括在治疗癌症和选择性诱导细胞凋亡方面使用化合物的方法。揭示了具有较低神经毒性效应的化合物。
  • ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS
    申请人:The Board of Trustees of the University of Illinois
    公开号:US20160176833A1
    公开(公告)日:2016-06-23
    The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.
    这项发明提供了用于调节某些酶的化合物和组合物。这些化合物和组合物可以诱导细胞死亡,特别是癌细胞死亡。该发明还提供了合成和使用这些化合物和组合物的方法,包括在治疗癌症和选择性诱导细胞凋亡中使用这些化合物和组合物的方法。
  • PARTICULATE DRUG DELIVERY METHODS
    申请人:The Board of Trustees of the University of Illinois
    公开号:US20150210659A1
    公开(公告)日:2015-07-30
    The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.
    本发明提供了可用于调节某些酶的化合物和组合物。这些化合物和组合物可以诱导细胞死亡,特别是癌细胞死亡。本发明还提供了合成和使用这些化合物和组合物的方法,包括在治疗癌症和选择性诱导细胞凋亡方面使用这些化合物和组合物的方法。
  • Compositions and Methods Including Cell Death Inducers and Procaspase Activation
    申请人:HERGENROTHER Paul J.
    公开号:US20110257398A1
    公开(公告)日:2011-10-20
    Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3.
查看更多